Larger, transdiagnostic studies are needed to address MMP-9 sensitivity and specificity to psychosis in order to examine if MMP-9 can be used as a peripheral biomarker to identify vulnerable individuals or to monitor treatment response. This evidence concerns the gene MMP9 and psychotic disorder.